Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients

被引:30
|
作者
Jing, Sun [1 ]
Kezhou, Yu [1 ]
Hong, Zhang [1 ]
Qun, Wang [1 ]
Rong, Wang [1 ]
机构
[1] Shandong Univ, Dept Kidney, Shandong Prov Hosp, Jinan 250021, Peoples R China
关键词
peritoneal dialysis; peritoneal fibrosis; renin-angiotensin system; ENDOTHELIAL GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; VASCULAR-PERMEABILITY FACTOR; MESOTHELIAL CELLS; RECEPTOR BLOCKERS; ACE-INHIBITORS; FACTOR-BETA; MEMBRANE; MECHANISMS; GLUCOSE;
D O I
10.1111/j.1440-1797.2009.01162.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aim: Long-term peritoneal dialysis (PD) may lead to peritoneal fibrosis and ultrafiltration failure. It had been demonstrated that the renin-angiotensin system (RAS) plays a key role in the regulation of peritoneal function in rats on PD. We investigated the effects of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) on long-term PD patients. Methods: We analyzed data from 66 patients treated with PD therapy at our centre for at least 12 months retrospectively, during which time at least two peritoneal equilibration tests (PET) were performed. Thirty-eight patients were treated with ACE/angiotensin II (AII) inhibitors (ACE/ARB group); the other 28 received none of the above drugs during the entire follow up (control group). The expression of fibronectin, transforming growth factor-beta 1 (TGF-beta 1), Aquaporin1 (AQP1) and vascular endothelial growth factor (VEGF) in the overnight effluent were examined by enzyme-linked immunosorbent assay. Results: The demographic data of the two groups showed no difference during the study. No difference between the groups was found with respect to residual renal function (RRF) at the start for both groups by the end of follow up, decreased in the vast majority of patients from both groups (P = 0.014). After 12 months, a significant difference in ultrafiltration was found between the two groups: in the control group it had decreased, while it had not changed in the ACE/ARB group (P < 0.05). In comparison with the baseline level, expression of fibronectin, TGF-beta 1 and VEGF in dialysate effluent were significantly increased except for AQP1 in the control group (P < 0.05), but not in the ACE/ARB group (P > 0.05). Conclusion: The findings suggest that ACE/AII inhibitors appeared to have a slower rate of decline in ultrafiltration and RRF, effectively protect against peritoneal fibrosis in long-term peritoneal dialysis. Long-term follow up seems to be required to draw more conclusions.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 50 条
  • [1] The effect of renin-angiotensin system inhibitors on intact parathyroid hormone levels in peritoneal dialysis patients
    Gao, Luyan
    Wang, Zhi
    Feng, Sheng
    Jiang, Shan
    Ouyang, Han
    Shi, Yongbing
    Shen, Huaying
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2015, 16 (04) : 1260 - 1265
  • [2] Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis
    Nakamoto, Hidetomo
    Imai, Hiroe
    Fukushima, Rie
    Ishida, Yuji
    Yamanouchi, Yasuhiro
    Suzuki, Hiromichi
    PERITONEAL DIALYSIS INTERNATIONAL, 2008, 28 : S83 - S87
  • [3] Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis
    Zhang, Zhen
    Jiang, Na
    Ni, Zhaohui
    FRONTIERS OF MEDICINE, 2017, 11 (03) : 349 - 358
  • [4] Influence of Renin-Angiotensin-Aldosterone System-Blocking Drugs on Peritoneal Membrane in Peritoneal Dialysis Patients
    Rupnik, Alijana Trost
    Pajek, Jernej
    Gucek, Andrej
    Osredkar, Josko
    Kovac, Damjan
    Bren, Andrej
    Klancic, Dimitrij
    Saksida, Silvan
    Rus, Igor
    Globokar, Mateja
    Drozg, Andrej
    Lesnik, Marjeta
    Plesivcnik, Zala
    Ekart, Robert
    Lopert, Simona
    Lindic, Jelka
    THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 (04) : 425 - 430
  • [5] A review of research progress on mechanisms of peritoneal fibrosis related to peritoneal dialysis
    Li, Jin'e
    Liu, Yinghong
    Liu, Jianping
    FRONTIERS IN PHYSIOLOGY, 2023, 14
  • [6] Selected indices of peritoneal fibrosis in patients undergoing peritoneal dialysis
    Penar, Jozef
    Weyde, Waclaw
    Krajewska, Magdalena
    Madziarska, Katarzyna
    Golebiowski, Tomasz
    Szymczak, Maciej
    Klak, Renata
    Klinger, Marian
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2009, 63 : 200 - 204
  • [7] Gene delivery in peritoneal dialysis related peritoneal fibrosis research
    Li Xie-jia
    Sun Lin
    Xiao Li
    Liu Fu-you
    CHINESE MEDICAL JOURNAL, 2012, 125 (12) : 2219 - 2224
  • [8] Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients
    Ribeiro, Silvia Carreira
    Figueiredo, Ana Elizabeth
    Barretti, Pasqual
    Pecoits-Filho, Roberto
    de Moraes, Thyago Proenca
    AMERICAN JOURNAL OF NEPHROLOGY, 2017, 46 (02) : 150 - 155
  • [9] Role of Spironolactone Chalcone in the Prevention of Peritoneal Fibrosis in Patients with Peritoneal Dialysis
    Han, Liang
    Yang, Xiao-Dong
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2015, 14 (10) : 1893 - 1897
  • [10] Role of macrophages in peritoneal dialysis-associated peritoneal fibrosis
    Chu, Chenling
    Huang, Ying
    Cao, Luxi
    Ji, Shuiyu
    Zhu, Bin
    Shen, Quanquan
    RENAL FAILURE, 2025, 47 (01)